Table 1.

Demographics and key interventions of travelers to Brazil (N = 599)

	Brazil travelers n (%)
Male	284 (47)
Mean age in years (IQR)	33 (23–52)
Country of origin Brazil	45 (8)
Mean duration in days (IQR)	15 (10–28)
Trip duration
<2weeks	268 (45)
2–4weeks	189 (32)
1–4 months	89 (15)
4+ months	36 (6)
Comorbidities
Immunocompromised	19 (3)
Pregnant	1 (0.2)
Medical comorbidity	74 (12)
Accommodation
Hotel or hostel	354 (59)
Home/local residence	186 (31)
Tent	22 (4)
Purpose for travel
Tourism	307 (51)
Visiting friends and relatives	127 (21)
Business	86 (14)
Education/research	38 (6)
Missionary/volunteer	17 (3)
Key interventions *
Travelers’ diarrhea—total prescriptions	509/596 (85)
Ciprofloxacin	408/596 (69)
Azithromycin	87/596 (15)
Levofloxacin	13/499 (3)
Rifaximin	1/437 (0.2)
Malaria—total chemoprophylaxis	232/595 (39)
Atovaquone/proguanil	189/595 (32)
Mefloquine	22/595 (4)
Chloroquine	15/595 (3)†
Doxycycline	6/595 (1)
Primaquine	0/437
Vaccinations
Influenza at travel clinic visit	84/582 (14)
Past vaccination‡	172/298 (58)‡
Hepatitis A at travel clinic visit	293/583 (50)
Past vaccination	125/320 (39)
Hepatitis B at travel clinic visit	62/582 (11)
Past vaccination	158/332 (48)
Rabies at travel clinic visit	16/582 (3)
Past vaccination	14/266 (5)
Typhoid at travel clinic visit	337/583 (58)
Past vaccination	157/379 (41)
Yellow fever at travel clinic visit	415/583 (71)
Past vaccination	157/366 (43)

^*Not all respondents answered each question regarding key interventions, therefore denominators are shown for clarification.

^†The Brazil travelers given chloroquine were also traveling to other Latin American countries where chloroquine was appropriate chemoprophylaxis.

^‡May include past season vaccine, thus may not be specific for the current season.